DEFR14A: TNF Pharmaceuticals Proposes Reverse Stock Split, Share Increase, and Stated Value Adjustment for Preferred Stock

TNF Pharmaceuticals seeks stockholder approval for a reverse stock split to meet Nasdaq listing requirements, an increase in authorized shares for future financing, and an adjustment to the stated value of preferred stock.

Summary

• TNF Pharmaceuticals is seeking stockholder approval for several key proposals at its upcoming annual meeting.
• The proposals include a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, with a ratio ranging from 1-for-2 to 1-for-100.
• The company also proposes increasing the number of authorized common shares from 250,000,000 to 1,250,000,000 to provide flexibility for future financing and corporate opportunities.
• Additionally, TNF Pharmaceuticals is seeking authorization to increase the stated value of Series F and Series F-1 Convertible Preferred Stock from $1,000 to a maximum of $1,125 per share, with the Series F Preferred Stock automatically increasing to $1,100 per share upon approval.
• The annual meeting will be held virtually on May 20, 2025.
• The board recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting necessary corporate actions. While the reverse stock split and share increase are aimed at improving the company's position, they also carry inherent risks.

Positives

• The reverse stock split aims to maintain the company's Nasdaq listing, potentially increasing investor confidence.
• Increasing authorized shares provides flexibility for future capital raising and strategic transactions.
• Adjusting the stated value of preferred stock could facilitate mutually beneficial adjustments to existing terms, better align interests and help the Company manage its capital structure more efficiently.

Negatives

• The reverse stock split may not increase the stock price long-term and could decrease liquidity.
• The reverse stock split could result in some stockholders owning odd lots, which may be more difficult to sell.
• Increasing the stated value of preferred stock may increase the liquidation preference and lead to dilution of common stockholders.

Risks

• The reverse stock split may not increase the stock price or maintain Nasdaq listing compliance.
• The reverse stock split could decrease the liquidity of the common stock.
• The increase in authorized shares could dilute existing stockholders' ownership.
• The increase in the stated value of preferred stock may increase the liquidation preference and lead to dilution of common stockholders.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements and secure financial flexibility for future growth through the proposed actions.

Management Comments

• Joshua Silverman, Chairman of the Board, urges stockholders to submit their vote as soon as possible.
• The Board of Directors recommends a vote FOR the Election of Directors, the Auditor Ratification Proposal, the Reverse Stock Split Proposal, the Share Increase Proposal, the Adjournment Proposal and the Preferred Stock Proposal.

Industry Context

Many companies facing similar listing compliance issues consider reverse stock splits to increase their share price and maintain their listing on major exchanges.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies facing delisting from exchanges like Nasdaq, with companies such as AYRO Inc. and Petros Pharmaceuticals, Inc. having undertaken similar actions.
• Increasing authorized shares is a standard practice to provide companies with the flexibility to raise capital and pursue strategic opportunities, aligning with the corporate governance strategies of companies like Synaptogenix Inc., Femasys Inc., and Pharmacyte Biotech, Inc.

Stakeholder Impact

• The reverse stock split and share increase could impact the value and liquidity of stockholders' investments.
• The proposals aim to improve the company's financial position, potentially benefiting employees and other stakeholders in the long term.

Next Steps

• Stockholder vote on the proposals at the annual meeting on May 20, 2025.
• Board determination on whether and when to implement the reverse stock split and share increase.
• Potential filing of amendments to the Certificate of Incorporation with the Secretary of State of Delaware.

Key Dates

Keywords

reverse stock split, authorized shares, preferred stock, proxy statement, annual meeting, TNF Pharmaceuticals, Nasdaq, corporate governance, stockholders